2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2262

CR6086 a New Potent EP4 Receptor Antagonist with Immunomodulatory Activities
Abstract Number: 2263

Apolipoprotein E Regulates Inflammation and Joint Destruction during Antigen-Induced Arthritis (AIA)
Abstract Number: 2264

Lack of Obesity-Related Changes in Adipocytes and Inflammatory Cells in the Infrapatellar Fat Pad (IFP): A Different Type of Fat?
Abstract Number: 2265

NET-Inducing Capacity Is a Biomarker in ANCA-Associated Vasculitis Independent of ANCA Antibodies
Abstract Number: 2266

A Melanocortin Fusion Peptide (AQB-565) Optimized for Melanocortin Receptor Engagement Significantly Reduces Inflammation in an In Vivo model of Acute Gout
Abstract Number: 2267

AMP-Activated Protein Kinase: A Target for Methotrexate in Macrophages
Abstract Number: 2268

Fructose Amplifies Inflammatory Potential in Human Monocytic Cells Via Reduction of AMP-Activated Protein Kinase Activity
Abstract Number: 2269

Proteinaceous Amorphous Calcium Carbonates As a Novel Family of Crystals in Synovial Fluid from Symptomatic Joints
Abstract Number: 2270

Inflammasome/IL-1β Activation Induced By Calcium Pyrophosphate Dihydrate Crystals Is Mainly Driven By a P2X7 Receptor-Independent Potassium Efflux
Abstract Number: 2271

Mutation in Osteoprotegerin Gene: Early-Onset Osteoarthritis and Chondrocalcinosis in a US Family of Italian/German Ancestry
Abstract Number: 2272

The Influence of Genetic Variants on Renal Uric Acid Excretion in Response to Frusemide
Abstract Number: 2273

Trans-Ancestral Meta-Analysis Identifies Nine New Loci Associated with Serum Uric Acid Concentrations
Abstract Number: 2274

Evidence of Phospho-Degron Regulating Expression of Urate Secretory Transporter ABCG2
Abstract Number: 2275

Genome-Wide Association Study of Gout in New Zealand Polynesian People
Abstract Number: 2276

Pleiotropic Effect of ABCG2 in Gout

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].